Of note, exendin-phe1 acted as a competitive antagonist against the -arrestin response to GLP-1 itself, suggesting that it might reduce the in vivo -arrestin recruitment by endogenous GLP-1 (Supplementary Fig
How to choose a safer provider If you decide to proceed with injections, rigorous vetting is essential
In the phase 3 SLIMMER trial published in The Lancet Diabetes & Endocrinology last year, ecnoglutide achieved weight loss of 15.1% at 48 weeks, with no evidence of a plateauing of effect, along with improvements in waist circumference, blood pressure, lipid profile, HbA1c, fasting glucose, and insulin levels
Also, as mentioned, it rescued the pressure fall in the lower esophageal and pyloric sphincter whatever it appeared after intra(per)-oral application of strong alcohol at the tongue, swallowed, without or with the immediate subsequent intragastric application of strong alcohol as well as after classic intragastric application of strong alcohol
Furthermore, evidence suggests that DPP-4 inhibitors may increase risk of hospitalization due to CHF and probably increase the risk for MACE and progression of CKD
